{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:46:12Z","timestamp":1782902772206,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a rare autoimmune disorder affecting peripheral nerves, is associated with substantial societal costs. This study assesses healthcare utilization and productivity losses across varying levels of patient disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were obtained from Adelphi\u2019s CIDP Disease Specific Programme\u2122 (September 2022\u2013April 2023), a digital, international, real-world survey involving neurologists and their patients (UK, France, Germany, Italy, Spain). Disability was measured using the Inflammatory Neuropathy Cause and Treatment (INCAT; range: 0\u201310), and categorized as mild (\u22642), moderate (3\u20134), or severe (\u22655). Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f199). Associations between disability level and healthcare utilization and lost productivity were evaluated using linear regression, adjusting for age and time since diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 542 patients, 236 (43.5%) had mild, 189 (34.9%) moderate, and 117 (21.6%) severe disability. Treatment rates increased with severity (receiving treatment: mild 78.4%, moderate 89.9%, severe 92.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). The proportion of patients receiving informal care rose sharply with increasing disability (mild 7.2%, moderate 31.2%, severe 62.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Hospitalizations in the 12\u202fmonths prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and ICU stays (0.0, 0.7, 3.9% respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001 for both). Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CIDP is associated with substantial healthcare utilization that increases with increasing disability, highlighting the progressive functional decline associated with more severe disease. In addition to direct healthcare demands, CIDP imposes considerable caregiver support needs, changes in living conditions, and productivity losses. Together, these findings underscore the wide-ranging impact of CIDP and the need for comprehensive management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1846192","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:07:01Z","timestamp":1782900421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare utilization and productivity losses associated with CIDP: results from an international survey"],"prefix":"10.3389","volume":"17","author":[{"given":"Febe","family":"Brackx","sequence":"first","affiliation":[{"name":"Services in Health Economics","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Arvin-Berod","sequence":"additional","affiliation":[{"name":"Argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Paci","sequence":"additional","affiliation":[{"name":"Argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Maria","family":"Van Dongen","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Bosmans","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wright","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Faust","sequence":"additional","affiliation":[{"name":"GBS CIDP Selbsthilfe NRW","place":["Neuss-Uedesheim, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dewilde","sequence":"additional","affiliation":[{"name":"Services in Health Economics","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/JNS5.12053","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go","volume":"19","author":"Nobile-Orazio","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/JNS.12455\/SUPINFO","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40120-025-00732-y","article-title":"Patient experience of chronic inflammatory demyelinating polyneuropathy (CIDP): a qualitative exploration of signs, symptoms, and health-related quality of life impacts","volume":"14","author":"Roberts","year":"2025","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"108017","DOI":"10.1016\/j.clineuro.2023.108017","article-title":"Impact of social-functioning and sleep on quality of life in chronic inflammatory demyelinating polyneuropathy","volume":"234","author":"Englezou","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","article-title":"A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"38","author":"Allen","year":"2021","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e00923","DOI":"10.1002\/brb3.923","article-title":"Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis","volume":"8","author":"Le Masson","year":"2018","journal-title":"Brain Behav"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ene.12245","article-title":"Economic costs and quality of life in chronic inflammatory neuropathies in southeast England","volume":"21","author":"Mahdi-Rogers","year":"2014","journal-title":"Eur J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0206205","DOI":"10.1371\/journal.pone.0206205","article-title":"The economic burden of CIDP in the United States: a case-control study","volume":"13","author":"Divino","year":"2018","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/MUS.26315","article-title":"Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany","volume":"58","author":"Mengel","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40273-016-0468-y","article-title":"The valuation of informal care in cost-of-illness studies: a systematic review","volume":"35","author":"Oliva-Moreno","year":"2017","journal-title":"PharmacoEconomics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jval.2012.05.009","article-title":"The inclusion of informal care in applied economic evaluation: a review","volume":"15","author":"Goodrich","year":"2012","journal-title":"Value Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/BMJOPEN-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/MUS.24207","article-title":"INCAT disability score: a critical analysis of its measurement properties","volume":"50","author":"Breiner","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1111\/ene.15815","article-title":"Chronic inflammatory neuropathies and their impact on activities and participation","volume":"30","author":"Wonink","year":"2023","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1846192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:07:02Z","timestamp":1782900422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1846192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":19,"alternative-id":["10.3389\/fneur.2026.1846192"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1846192","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1846192"}}